Please login to the form below

Not currently logged in

AZ’s Farxiga cuts risk of death in chronic kidney disease

Detailed results revealed at the European Society of Cardiology virtual congress

AstraZeneca (AZ) has revealed some impressive results from a phase 3 study of its heart failure drug Farxiga in chronic kidney disease (CKD) at the European Society of Cardiology (ESC) virtual congress.

In the DAPA-CKD trial, Farxiga (dapagliflozin) added to standard of care reduced the risk of cardiovascular or renal death and worsening of renal function by 39% compared to placebo in patients with CKD.

The results were consistent in patients both with and without type 2 diabetes, opening up the potential market for the SGLT2 inhibitor if it wins approval in this indication. The trial also met all key secondary endpoints, including significantly reducing death from any cause by 31% compared to placebo.

CKD affects nearly 700 million people worldwide, many of which are still undiagnosed, and is characterised by decreased kidney function. It is often caused by diabetes, hypertension and glomerulonephritis.

“With today’s results, Farxiga becomes the first SGLT2 inhibitor proven to significantly prolong the survival of patients with chronic kidney disease with and without type 2 diabetes and we look forward to sharing these data with regulatory authorities around the world,” said Mene Pangalos, executive vice president, biopharmaceuticals R&D at AZ.

“Farxiga is also the first medicine in its class to demonstrate benefit in treating both heart failure and chronic kidney disease in patients with and without type 2 diabetes, and reduce the risk of hospitalisation for heart failure and nephropathy in type 2 diabetes,” he added.

In March, the US Food and Drug Administration (FDA) fast-tracked Farxiga’s rival Jardiance (empagliflozin), co-developed by Eli Lilly and Boehringer Ingelheim, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.

This accelerated review was based on exploratory results from the EMPA-REG OUTCOME trial, which found that treatment with Jardiance reduced the risk of new-onset and worsening kidney disease by 39% in adults with type 2 diabetes and established cardiovascular disease compared with placebo.

Lilly/Boehringer are studying Jardiance in the ongoing EMPA-KIDNEY study to confirm Jardiance’s efficacy in CKD in patients with and without diabetes. The results from this study are not likely to be available until 2022, however, priming AZ's Farxiga to become the first SGLT2 inhibitor to win approval in CKD.

Article by
Lucy Parsons

2nd September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....